Key facts
- Zenshine Pharmaceuticals (Nanjing) Group’s last known valuation is $354.4M (Jan 2026).
- It has raised $126.6M; the latest was IPO in Jan 2026.
- Notable investors include China Capital Management, CMG SDIC Fund, Tailong VC, Proxima Ventures (China), Changxing Fund — 21 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Zenshine Pharmaceuticals (Nanjing) Group
- ·The full record, as it builds
Funding rounds
No funding rounds for Zenshine Pharmaceuticals (Nanjing) Group are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zenshine Pharmaceuticals (Nanjing) Group
Developer and provider of innovative antiviral and oncology therapies designed for unmet clinical needs in viral infections, cancer, and inflammatory diseases. The company provides a portfolio including the next-generation influenza polymerase acidic protein inhibitor baloxavir marboxil and ENPP1 inhibitors for cancer treatment, enabling healthcare providers with more effective and accessible therapeutic options.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2018
- Employees
- 77
- Website
- zenshine-pharma.com/
- Ownership
- In IPO Registration
Zenshine Pharmaceuticals (Nanjing) Group doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zenshine Pharmaceuticals (Nanjing) Group shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zenshine Pharmaceuticals (Nanjing) Group in its N-PORT filings yet. We sweep new filings monthly.